Literature DB >> 31231439

Development of a Novel Imaging Agent for Determining Albumin Uptake in Solid Tumors.

S Daum1, J P Magnusson1, L Pes1, J Garcia Fernandez1, S Chercheja1, F Medda1, F I Nollmann1, S D Koester1, P Perez Galan1, A Warnecke1, K Abu Ajaj1, Felix Kratz1.   

Abstract

PURPOSE: The purpose of this study was to investigate the albumin-binding compound 111In-C4-DTPA as an imaging agent for the detection of endogenous albumin accumulation in tumors.
METHODS: 111In-C4-DTPA was injected in healthy nude mice for pharmacokinetic and biodistribution studies (10 min, 1, 6, 24, and 48 h, n = 4) and subsequently in tumor-bearing mice for single-photon emission computed tomography/X-ray-computed tomography (SPECT/CT) imaging studies. Four different human tumor xenograft models (LXFL529, OVXF899, MAXFTN401, and CXF2081) were implanted subcutaneously unilaterally or bilaterally (n = 4-8). After intravenous administration of 111In-C4-DTPA, SPECT/CT images were collected over 72 h at 4-6 time points. Additionally, gamma counting was performed for the blood, plasma, lungs, heart, liver, spleen, kidneys, muscle, and tumors at 72 h post-injection.
RESULTS: 111In-C4-DTPA bound rapidly to circulating albumin upon injection, and the radiolabeled albumin conjugate thus formed was stable in murine and human serum. SPECT/CT images demonstrated a time-dependent uptake with a maximum of 2.7-3.8% ID/cm3 in the tumors at approximately 24 h post-injection and mean tumor/muscle ratios in the range of 3.2-6.2 between 24 and 72 h post-injection. The kidneys and bladder were the predominant elimination organs. Gamma counting at 72 h post-injection showed 1.3-2.5% ID/g in the tumors and mean tumor/muscle ratios in the range of 4.9-9.4.
CONCLUSION: 111In-C4-DTPA bound rapidly to circulating albumin upon injection and showed time-dependent uptake in the tumors demonstrating a potential for clinical application as a companion imaging diagnostic for albumin-binding anticancer drugs.

Entities:  

Keywords:  111In; Albumin; Drug carrier; Imaging agent; SPECT/CT imaging; Tumor accumulation

Year:  2019        PMID: 31231439      PMCID: PMC6554392          DOI: 10.1007/s13139-019-00587-w

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  24 in total

1.  A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy.

Authors:  F Kratz; R Müller-Driver; I Hofmann; J Drevs; C Unger
Journal:  J Med Chem       Date:  2000-04-06       Impact factor: 7.446

2.  Therapeutic radiopharmaceuticals.

Authors:  W A Volkert; T J Hoffman
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

3.  Protein transfer in tumor-bearing rats.

Authors:  A L BABSON; T WINNICK
Journal:  Cancer Res       Date:  1954-09       Impact factor: 12.701

4.  Crystal structure of human serum albumin at 2.5 A resolution.

Authors:  S Sugio; A Kashima; S Mochizuki; M Noda; K Kobayashi
Journal:  Protein Eng       Date:  1999-06

5.  Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.

Authors:  Felix Kratz; André Warnecke; Karin Scheuermann; Cornelia Stockmar; Jürgen Schwab; Peter Lazar; Peter Drückes; Norbert Esser; Joachim Drevs; Didier Rognan; Caterina Bissantz; Caterina Hinderling; Gerd Folkers; Iduna Fichtner; Clemens Unger
Journal:  J Med Chem       Date:  2002-12-05       Impact factor: 7.446

6.  Synthesis and Physicochemical Characterization of a New Gadolinium Chelate: The Liver-Specific Magnetic Resonance Imaging Contrast Agent Gd-EOB-DTPA.

Authors:  H. Schmitt-Willich; M. Brehm; Ch. L. J. Ewers; G. Michl; A. Müller-Fahrnow; O. Petrov; J. Platzek; B. Radüchel; D. Sülzle
Journal:  Inorg Chem       Date:  1999-03-22       Impact factor: 5.165

Review 7.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.

Authors:  H Maeda; J Wu; T Sawa; Y Matsumura; K Hori
Journal:  J Control Release       Date:  2000-03-01       Impact factor: 9.776

8.  Design of compounds having enhanced tumour uptake, using serum albumin as a carrier--Part II. In vivo studies.

Authors:  U Schilling; E A Friedrich; H Sinn; H H Schrenk; J H Clorius; W Maier-Borst
Journal:  Int J Rad Appl Instrum B       Date:  1992-08

9.  A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2.

Authors:  Ahmed M Mansour; Joachim Drevs; Norbert Esser; Farid M Hamada; Osama A Badary; Clemens Unger; Iduna Fichtner; Felix Kratz
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

10.  Different sites and modes of tracer injection for mapping the sentinel lymph node in patients with breast cancer.

Authors:  P Bianchi; G Villa; F Buffoni; G Agnese; M Gipponi; R Costa; C Maragliano; G Canavese; G Mariani
Journal:  Tumori       Date:  2000 Jul-Aug
View more
  3 in total

Review 1.  Deciphering albumin-directed drug delivery by imaging.

Authors:  Huiyu Hu; Jeremy Quintana; Ralph Weissleder; Sareh Parangi; Miles Miller
Journal:  Adv Drug Deliv Rev       Date:  2022-03-29       Impact factor: 17.873

2.  Human Serum Albumin Decorated Indocyanine Green Improves Fluorescence-Guided Resection of Residual Lesions of Breast Cancer in Mice.

Authors:  Zun Wang; Min Chen; Jing-Jing Liu; Rong-He Chen; Qian Yu; Gui-Mei Wang; Li-Ming Nie; Wen-He Huang; Guo-Jun Zhang
Journal:  Front Oncol       Date:  2021-03-08       Impact factor: 6.244

Review 3.  Theranostics in Boron Neutron Capture Therapy.

Authors:  Wolfgang A G Sauerwein; Lucie Sancey; Evamarie Hey-Hawkins; Martin Kellert; Luigi Panza; Daniela Imperio; Marcin Balcerzyk; Giovanna Rizzo; Elisa Scalco; Ken Herrmann; PierLuigi Mauri; Antonella De Palma; Andrea Wittig
Journal:  Life (Basel)       Date:  2021-04-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.